Radiopharm Theranostics Limited (RADX) Stock Score, Valuation & Financial Research
Radiopharm Theranostics Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 38/100.
Quick answer for RADX
Radiopharm Theranostics Limited currently has a Wall Street Score of 38/100. The stored market price is $1.98. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Radiopharm Theranostics Limited does
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of
RADX financial snapshot
- Wall Street Score:
- 38/100
- Current price:
- $1.98
- Market capitalization:
- $2.6M
- Revenue:
- $2.6M
- Net income:
- $-27.0M
- Free cash flow:
- $-25.8M
- Cash:
- $24.3M
- Total debt:
- $0
- EPS:
- -20.95
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is +11.1%.
- Free cash flow is $-25.8M, showing cash burn in the current stored period.
- The balance sheet shows $24.3M of cash versus $0 of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.2 points: RADX increased 0.2 points because Revenue improved by 2.2 points.
- The current research record carries a missing opportunity history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-05.
How to research RADX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.